Every year, World Toilet Day is observed to raise awareness about the global sanitation crisis and encourage action to solve it. The goal set by the United Nation is to achieve safe toilets for all by 2023, as a part of their Sustainable Development Goals.
The UN also states that 3.5 billion people live without proper sanitation and many children also lose their lives due to poor sanitation and unsafe water. This is why World Toilet Day is observed to raise awareness on this issue.
This year, the theme for World Toilet Day 2024 is "Toilets - A Place for Peace'. This focuses on the growing threat to sanitation that is caused by conflict, climate change, disaster and neglect. When there is a threat to using toilets, it can lead to many health risks.
Not using toilets for too long may lead to Urinary Tract Infection or UTI. For many who do not have access to clean toilets do not drink enough liquid or hold pee for too long. Doctors suggest that holding in pee for too long can cause bacteria to multiply and lead to UTI. By not drinking enough water, your bladder fails to tell the body to pee often, and can cause the bacteria to spread through the urinary tract, which can lead to infection.
Holding in pee for too long can also cause your bladder to stretch, making it difficult or even impossible for the bladder to contract and release pee normally. It can also damage your pelvic floor muscles or could lead to kidney stones.
To prevent such conditions, it is important that everyone has access to clean and safe toilets. In terms of history, the day was established in 2001, by the World Toilet Organization (WTO), which was founded by Jack Sim. However, it was officially recognised by the UN in 2013. The Government of Singapore worked with WTO to create the first UN resolution called Sanitation for All.
India too promotes safe and hygiene toilet through its Swachh Bharat Yojna.
Credit: iStock
The United States and other countries in the Americas are witnessing increasing influenza activity as the Northern Hemisphere enters the 2026–27 respiratory virus season.
In a November 17 epidemiological alert, the Pan American Health Organization (PAHO) and World Health Organization (WHO) urged countries to strengthen surveillance of respiratory viruses, prepare healthcare services for a possible increase in demand and accelerate seasonal influenza and respiratory syncytial virus (RSV) vaccination among priority groups before the peak of viral circulation.
The report noted that influenza, RSV and other respiratory viruses have gradually increased in the US. Overall respiratory virus activity is higher than typically observed at this time of year.
Influenza positivity increased from 7.6% in the week ending October 18 to 9.1% in the week ending October 25. Influenza A(H1N1)pdm09 emerged as the predominant subtype.
Influenza-like illness (ILI) activity was classified as high in two states, Louisiana and South Carolina. Hospital surveillance data also showed a gradual increase in influenza-associated hospitalisation rates.
Also read: US Respiratory Viruses In 2026: CDC Identifies 4 Illnesses To Watch
Canada is also witnessing an increase in influenza circulation, which began earlier than in previous post-pandemic seasons between 2022–23 and 2025–26.
Influenza positivity reached 10.8% in the week ending October 25, with activity shifting from low to moderate levels. Unlike the previous season, influenza A(H1N1)pdm09 is the predominant subtype.
COVID-19 circulation is also gradually increasing in Canada but remains low and below levels observed in previous seasons. SARS-CoV-2 positivity stood at 5.8%.
Hospitalisations associated with respiratory viruses are also rising, reaching 2.6 per 100,000 population. Influenza-associated hospitalisations reached 1.2 per 100,000, while the rate for COVID-19-associated hospitalisations was 1.3 per 100,000. However, PAHO/WHO noted that these rates remain low and within the expected range for this time of the season.
Read More: G155E H1N1 Mutation In US Raises Concerns: Can This Year’s Flu Shot Still Protect You?
Globally, influenza activity is following expected seasonal patterns, with a gradual increase over recent months in temperate and subtropical regions of the Northern Hemisphere. Influenza positivity in these regions is approaching 10%.
Some countries in North America, Central America and the Caribbean, as well as in Africa, Asia and Europe, have reported influenza positivity rates above 10%, according to the alert.
In contrast, influenza activity has declined over the past two months in temperate and subtropical regions of the Southern Hemisphere, where positivity has fallen to around 5%.
READ: Flu 2026: Symptoms To Watch For As New Season Begins
Alongside increasing influenza activity, PAHO/WHO highlighted high RSV circulation in some countries in the Northern Hemisphere.
Globally, RSV positivity rates above 10% were observed in some countries, particularly in tropical and subtropical regions.
The organization warned that the circulation of multiple respiratory viruses makes it important for countries to strengthen healthcare preparedness ahead of seasonal peaks.
PAHO/WHO has called on member states to strengthen integrated epidemiological and virological surveillance of respiratory viruses, including timely genomic characterization to monitor viral evolution.
It has also recommended that countries adjust healthcare preparedness and organizational plans in anticipation of a possible increase in demand for medical services.
The alert also urges countries to accelerate seasonal influenza and RSV vaccination among priority groups, in line with current recommendations and before periods of increased viral circulation.
Credit: AI
Canada's regulatory body Health Canada recently approved GLP-1 pill developed by pharmaceutical company Eli Lilly. The weight loss pill offers an alternative to injectable weight-loss and diabetes medications.
The development comes as new study suggests that GLP-1 drugs could be more effective than metformin in preventing Type 2 diabetes and improving blood sugar in people with obesity and prediabetes.
The newly approved drug, Foundayo (orforglipron) is approved for adults with obesity and have at least one related health condition. It is also approved to help manage Type 2 diabetes.
Unlike popular GLP-1 medications like Ozempic and Wegovy, which are administered through injections, Foundayo is taken orally once a day. The company expects the GLP-1 pill to become available in Canadian pharmacies in January 2027.
Foundayo contains orforglipron, a non-peptide GLP-1 receptor agonist. It mimics the action of glucagon-like peptide-1 (GLP-1), which is naturally-occurring hormone released by the gut after eating.
GLP-1 helps regulate blood sugar by stimulating insulin release when glucose levels increase. It also suppresses glucagon, a hormone that raises blood sugar, slows emptying of stomach and targets areas of the brain responsible for appetite. These effects, together, help improve blood sugar control, reduce hunger and support weight loss.
Unlike peptide-based GLP-1 medicines, orforglipron is a small molecule that can be absorbed orally without being broken down by digestive enzymes. It can also be taken without the food and water restrictions that come with some oral GLP-1 medications.
Novo Nordisk’s Rybelsus is already on the market in Canada, but it is only approved for Type 2 diabetes management and not for weight loss.
A separate study presented at the American Heart Association's Scientific Sessions 2026 compared GLP-1 medications to metformin in more than 256,000 adults with obesity and prediabetes.
Researchers found that people taking GLP-1 medications were 1.5 times more likely to return to normal blood sugar levels than those taking metformin. They also had a 31% lower risk of developing Type 2 diabetes and a 41% lower risk of death from any cause. GLP-1 users were also at lower risks of heart attacks, strokes and heart failure events.
But the study analysed health records rather than conducting a randomised clinical trial. It also grouped several GLP-1 medicines together, including semaglutide, tirzepatide, liraglutide and dulaglutide. Orforglipron was not among the drugs evaluated.
Study author Vinicius de Sousa Barzon Serra said, "Metformin is still a first-line treatment choice. It is safe, inexpensive and has a long track record. This is less about replacing one medication with another and more about discussing additional options with specific patients."
Common side effects of GLP-1 medications include gastrointestinal effects like nausea, vomiting, diarrhoea, constipation and abdominal discomfort. These symptoms are often more noticeable when treatment begins or doses increase.
Although oral medicines offer an alternative to injections, they are not suitable for everyone. It depend on a person's medical history, blood sugar levels, weight and other health conditions.
Credit: AI image
Pennsylvania has reported its eighth measles-associated death of 2026 as the US battles a major outbreak that cost it its measles elimination status.
The news came a day after the Pan American Health Organization (PAHO) announced that the US, Mexico, and Bolivia had lost their measles elimination status. The US had maintained their measles-free status since 2000.
Pennsylvania has recorded around 1,589 confirmed cases across 46 counties, prompting authorities to urge people to check their vaccination status and ensure they are adequately protected. The total number of cases in the US has crossed more than 5,700.
The latest death, confirmed on November 18, involved an unvaccinated resident of Clinton County who had tested positive for measles. Health authorities have not disclosed the individual's age or other relevant details. According to the Pennsylvania Department of Health, the state has also reported 315 hospitalisations linked to the outbreak.
With measles cases spreading everyday, questions about whether adults who received measles vaccines during childhood need another dose have emerged. Health experts believe that most people who have received the recommended two doses of the measles, mumps and rubella (MMR) vaccine do not need a booster.
According to the US Centers for Disease Control and Prevention (CDC), adults born in 1957 or later who do not have evidence of immunity should receive at least one dose of the MMR vaccine. But certain groups are recommended to receive two doses, separated by at least 28 days. These include:
People who have received two documented doses of the MMR vaccine, with the first administered at or after 12 months of age and the doses appropriately spaced, are considered protected for life.
Also read: Not Just US, Mexico & Bolivia Also Lose Measles-Free Status: RFK Jr & CDC Chief Respond
According to the CDC, adults born before 1957 are presumed to have immunity against measles because the virus circulated widely before the vaccine became available in 1963.
However, healthcare workers born before 1957 who do not have a history of previous measles infection should consider receiving two doses of the MMR vaccine.
People vaccinated between 1963 and 1967 with the older inactivated (killed) measles vaccine may also need another dose. This version was later found to be ineffective.
The MMR vaccine is a live attenuated vaccine, which means it contains weakened forms of the viruses.
Pregnant women and people with severe immune suppression should generally not receive it. Individuals with a history of severe allergic reactions to a previous dose or vaccine component should also seek medical advice.
People who are unsure about their vaccination history, immune status or need for another dose should consult their healthcare provider.
Measles is one of the most contagious infectious diseases. The virus spreads through respiratory droplets and airborne particles. They can remain active in the air for up to two hours after an infected person leaves an area.
Symptoms typically start with fever, cough, runny nose and red, watery eyes, followed by a rash that usually starts on the face and spreads across the body.
Complications can include pneumonia, brain inflammation (encephalitis), permanent disability and death. Infants, young children and people with weakened immune systems are vulnerable. The resurgence has been attributed to declining vaccination coverage.
© $2026 Times Horizon Private Limited